Update on Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares ofComon StockJuly 16, 2013 08:45 AM Eastern Daylight Time
pretty common sense
Excitement Among Proof-of-Concept Drug Companies Could Spill Over Into This Lesser-Known Name
Excitement from proof-of-concept stage drug companies like Aduro Biotech ( ADRO ) or Receptos (NASDAQ: RCPT) could spill over into the lesser-known Sunshine Heart (NASDAQ: SSH), whose device is in a pivotal study for the treatment of late-stage heart failure - a disease with prognosis as poor as the most aggressive cancers and no effective treatment options. The market opportunity is perhaps as largeas~$90 Billion.Part of the reason Aduro has performed amicably is that their approach to treating cancer is novel and potentially offers a favorable safety profile, particularly when compared to standard of care
4/15/15 ( GPRO ) was upgraded to "overweight" from "neutral" by analysts at Piper Jaffray.
The firm set its price target at $55, and noted the widespread adoption of the GoPro brand both by outdoor adventurists as well as daily users.
ADXS will be 1# winner
ADRO IPO $1.25 billion, ADXS mkt cap $500 million
GoPro Schedules First Quarter 2015 Financial Results for April 28, 2015
PR Newswire GoPro, Inc.
4/10 Schaffer Options : Longs Getting Behind GoPro ,High Volume Call Buying ,,, cont,,,,,,,,,